Product Description
Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes that catalyze the addition of poly(ADP-ribose) (PAR) subunits onto themselves and other acceptor proteins. (Sourced from: https://www.frontiersin.org/articles/10.3389/fmolb.2020.00191/full)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: National Health and Medical Research Council
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Prostate Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03334500 |
UPCC 13817 | P1 |
Active, not recruiting |
Prostate Cancer |
2027-02-11 |
2026-02-21 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/17/2026 |
News Article |
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer |
|
08/08/2025 |
News Article |
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results |
|
01/09/2025 |
News Article |
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions |
|
11/07/2024 |
News Article |
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results |